Latest news for Getinge (OTC:GNGBF) Stock

Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (34%), and life sciences (14%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales (U.S. 33% of sales), Asia-Pacific 25%, and Europe, Middle East, and Africa the remaining 30%.

Getinge AB

Getinge AB (GNGBF) Q1 2024 Earnings Call Transcript

Getinge AB (publ) reports Q2 results

Getinge AB (GNGBF) Q2 2024 Earnings Call Transcript

Protean Funds Scandinavia AB July 2024 Partner Letter

Teleflex Reinvesting In Growth, But Valuation Isn't That Compelling

Getinge AB (publ) 2024 Q3 - Results - Earnings Call Presentation

Getinge AB (publ) reports Q3 results

Protean Funds Scandinavia AB October 2024 Partner Letter

Getinge AB: Why We Think There's Confusion Of Frequency And Magnitude

Protean Funds Scandinavia AB November 2024 Partner Letter

ACASF

ADDHY

AMKAF

AMKBF

AMKBY

ATLCY

ATLFF

ATLKY

ATLPF

CCNTF

CTTMF

EKTAF

EKTAY

EQNR

ERIC

ERIXF

EVGGF

EVVTY

FBGBY

FBGGF

GNGBF

GNGBY

HOYFF

HXGBF

HXGBY

KOYJF

LOIMF

LYSFF

LYSFY

MHGVY

MNHVF

NTOIF

NTOIY

OUKPF

OUKPY

PRCT

RSLBF

SKBSY

SKSBF

STOHF

TGVSF

TRUBF

VLMTY

VOYJF

Press Releases

Getinge takes a leap forward in cardiovascular surgery with the 510(k) clearance for Vasoview Hemopro 3

Small Cap

Getinge's financial target 2024-2028: Adjusted EPS growth of above 12% on average

Earnings

Getinge Interim Report April-June 2024: Higher sales, stronger margins and product launches with significant added value for customers

Getinge to acquire Paragonix Technologies, a growth leader in the organ transplantation market

Getinge completes the acquisition of Paragonix Technologies

Getinge Interim Report July-September 2024: Strong order intake but temporary delivery disruptions had a negative impact on earnings

Getinge

Comments

Getinge

News

Latest news for Getinge (OTC:GNGBF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga